Cargando…

Pancreas Cancer Survival in the Gemcitabine Era

After multiple positive studies, gemcitabine, approved for the treatment of pancreas cancer by the FDA in 1977, became standard of care. Whether this therapeutic advance has translated into longer survival for pancreas cancer patients in general has not been established. This study, derived from SEE...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachtel, Mitchell S., Xu, K. Tom, Zhang, Yan, Chiriva-Internati, Maurizio, Frezza, Eldo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161658/
https://www.ncbi.nlm.nih.gov/pubmed/21892307
_version_ 1782210716726460416
author Wachtel, Mitchell S.
Xu, K. Tom
Zhang, Yan
Chiriva-Internati, Maurizio
Frezza, Eldo E.
author_facet Wachtel, Mitchell S.
Xu, K. Tom
Zhang, Yan
Chiriva-Internati, Maurizio
Frezza, Eldo E.
author_sort Wachtel, Mitchell S.
collection PubMed
description After multiple positive studies, gemcitabine, approved for the treatment of pancreas cancer by the FDA in 1977, became standard of care. Whether this therapeutic advance has translated into longer survival for pancreas cancer patients in general has not been established. This study, derived from SEER (Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute) data, compared the survival experiences of the gemcitabine (1998–2004) and pre-gemcitabine (1988–1997) eras for 7,151 patients who had metastatic disease and did not undergo extirpative surgery, 14,369 patients who had not undergone surgery and had metastases, 5,042 patients who had undergone surgery and did not have metastases, and 5,011 patients who had undergone surgery and had metastases. Calculated survival time ratios (TR) were adjusted for radiotherapy history, grade, nodal status, loco-regional extent of disease, age, race, and gender. For those who did not undergo extirpative surgery, improvements in survival in the gemcitabine era (1998–2004) versus the prior time period (1988–1997) seen for patients with metastatic cancer (TR = 1.20, 95% c.i. 1.15–1.25) were not seen for those without metastatic cancer (TR = 1.05, 95% c.i. 1.00–1.15). For those who did undergo extirpative surgery, improvements were much more dramatic for those with metastatic cancer (TR = 1.61, 95% c.i. 1.45–1.80) than those without metastases (TR = 1.23, 95% c.i. 1.15–1.31). The results are consistent with the notion that the promising findings with respect to gemcitabine in the controlled clinical trials have found expression in the general population of patients with pancreas cancer.
format Online
Article
Text
id pubmed-3161658
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-31616582011-09-02 Pancreas Cancer Survival in the Gemcitabine Era Wachtel, Mitchell S. Xu, K. Tom Zhang, Yan Chiriva-Internati, Maurizio Frezza, Eldo E. Clin Med Oncol Original Research After multiple positive studies, gemcitabine, approved for the treatment of pancreas cancer by the FDA in 1977, became standard of care. Whether this therapeutic advance has translated into longer survival for pancreas cancer patients in general has not been established. This study, derived from SEER (Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute) data, compared the survival experiences of the gemcitabine (1998–2004) and pre-gemcitabine (1988–1997) eras for 7,151 patients who had metastatic disease and did not undergo extirpative surgery, 14,369 patients who had not undergone surgery and had metastases, 5,042 patients who had undergone surgery and did not have metastases, and 5,011 patients who had undergone surgery and had metastases. Calculated survival time ratios (TR) were adjusted for radiotherapy history, grade, nodal status, loco-regional extent of disease, age, race, and gender. For those who did not undergo extirpative surgery, improvements in survival in the gemcitabine era (1998–2004) versus the prior time period (1988–1997) seen for patients with metastatic cancer (TR = 1.20, 95% c.i. 1.15–1.25) were not seen for those without metastatic cancer (TR = 1.05, 95% c.i. 1.00–1.15). For those who did undergo extirpative surgery, improvements were much more dramatic for those with metastatic cancer (TR = 1.61, 95% c.i. 1.45–1.80) than those without metastases (TR = 1.23, 95% c.i. 1.15–1.31). The results are consistent with the notion that the promising findings with respect to gemcitabine in the controlled clinical trials have found expression in the general population of patients with pancreas cancer. Libertas Academica 2008-04-29 /pmc/articles/PMC3161658/ /pubmed/21892307 Text en © 2008 the author(s), publisher and licensee Libertas Academica Ltd. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license http://creativecommons.org/licenses/by/3.0/).
spellingShingle Original Research
Wachtel, Mitchell S.
Xu, K. Tom
Zhang, Yan
Chiriva-Internati, Maurizio
Frezza, Eldo E.
Pancreas Cancer Survival in the Gemcitabine Era
title Pancreas Cancer Survival in the Gemcitabine Era
title_full Pancreas Cancer Survival in the Gemcitabine Era
title_fullStr Pancreas Cancer Survival in the Gemcitabine Era
title_full_unstemmed Pancreas Cancer Survival in the Gemcitabine Era
title_short Pancreas Cancer Survival in the Gemcitabine Era
title_sort pancreas cancer survival in the gemcitabine era
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161658/
https://www.ncbi.nlm.nih.gov/pubmed/21892307
work_keys_str_mv AT wachtelmitchells pancreascancersurvivalinthegemcitabineera
AT xuktom pancreascancersurvivalinthegemcitabineera
AT zhangyan pancreascancersurvivalinthegemcitabineera
AT chirivainternatimaurizio pancreascancersurvivalinthegemcitabineera
AT frezzaeldoe pancreascancersurvivalinthegemcitabineera